Respiratory care challenges
In the UK, hospital admissions for lung disease have risen over the past seven years at three times the rate of all other admissions. Respiratory illness accounts for 700,000 hospital admissions and 6 million bed days per year. The British Lung Foundation estimates that the direct healthcare cost of lung disease is £9.9 billion per year. It is a national strategy to reduce these numbers by enabling earlier identification and better self management of respiratory disease.
NHS respiratory services face growing pressures – fuelled by backlogged appointments, increased diagnostic referrals, and more complex follow-up pathways. Patients are now waiting longer for first-time appointments and experience delays in follow-up care. On-site clinic attendance also places vulnerable patients at risk of infection. Care pathways must be adapted to provide more efficient and safer care for patients. Personalised outpatient pathways are recognised in NHS policy, which ensure patients have the tools and education to self manage from home and receive the care at the right time and the right place.
patientMpower provides digital care solutions across a range of pulmonary conditions, including Interstitial Lung Disease (inc pulmonary fibrosis), cystic fibrosis, lung transplant and COVID-19. The patientMpower application enables remote monitoring of patients with chronic or acute respiratory conditions, to help patients to manage their condition from home, and support increased virtual care delivery avoiding unnecessary hospital visits.
Remote monitoring using the patientMpower platform reduces pressure on both in-patient and out-patient hospital resources, empowers patient self-care, and enables the rapid identification and earlier management of patient deterioration or disease exacerbations. Evidenced outcomes include:
At the Addenbrooke’s paediatric Cystic Fibrosis unit patientMpower is enabling a hybrid model of face-to-face and virtual care. The project has:
- Reduced the burden of out-patient visits on patients and families by 50%
- Increase overall clinic capacity
- Facilitate shared care between hub and spoke centres
- Identified potential complications earlier
At NYU Langone, a leading lung transplant centre in the US, patientMpower supported:
- A 66% reduction in out-patient visits
- Increased patient reassurance
- Successful identification and management of organ rejection
- Successful early identification of COVID-19 infection